Clinical trial · Observational
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
NCT07056205CI-TRIAL-00091942enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- archived histological slides and immune-stained slides of 100 patient with breast cancer
Primary outcomes (1)
- measure
- Comparison between initial and recurrent breast cancer in immunohistochemical expression of ER,PR and HER2/neu
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
- Correlate the results of immunohistochemical expression of ER,PRand HER2/neu with the patients age ,sex,nodal status and lymphovascular invasion
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors. Exclusion Criteria: * Cases with insufficient clinical of pathological data. Deficient ER, PR and HER2/neu status in either initial or recurrent tumor
References
Publications (0)
Data not yet available
No reference posted for this study.